hotspot -WSS

hotspot

author：comprehensive 2025-10-01 10:57:05 - browse：22

Powdered ibogaine against a white background. — Tabernanthe iboga, the shrub that contains the psychedelic substance ibogaine. Wikimedia Commons

The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction, the federal government’s top addiction researcher said Thursday.

The remarks from Nora Volkow, the longtime director of the National Institute on Drug Abuse, serve as a cautionary note amid widespread enthusiasm about ibogaine, a naturally occurring substance that drug companies and researchers have increasingly cast as a potential paradigm-shifting addiction treatment.

But its potential cardiac side effects could stand in the way of receiving approval from the Food and Drug Administration, Volkow said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： HCA sued by state AG for quality issues at Mission Health

focus

WSS

Retired US general questions alleged Putin, Prigozhin meeting

Retired US general questions alleged Putin, Prigozhin meeting

Hospitals owned by private equity see complications spike 25%

Why health care costs have stayed mostly flat since 2010

Why ADHD is under

How the political right came to back psychedelics to treat trauma

focus

hotspot

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Iowa House, Senate pass 6

Medical leaders decry Supreme Court decision on affirmative action

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

State Dept. review finds Biden bears some blame for Afghanistan failures

Beach reads and more: STAT's 2023 summer book list

Medicare details structure of new drug price negotiation program

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Hollywood unions extend contract negotiations for actors

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

In Spain, a hospital brews its own CAR

Three trends to watch in biotech in 2024

What STAT readers think about the FDA and patient advocacy

In Spain, a hospital brews its own CAR

Grail spinoff by Illumina should end disastrous merger attempt

Retired US general questions alleged Putin, Prigozhin meeting

hotspot

focus

focus

entertainment